Flourish Research/Merritt Island Medical Research
Welcome,         Profile    Billing    Logout  
 6 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Galloway, Christopher
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Completed
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
05/24
STEM-PD, NCT04797611: STEM-Parkinson's Disease

Completed
N/A
188
Europe, US
TNM Device, tvCVS
Scion NeuroStim
Parkinson Disease, Parkinson's Disease and Parkinsonism
12/24
12/24
Rice, Taylor
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
Feinberg, Marc
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
01/24
02/24
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
ADAPT oculus, NCT06558279: A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

Recruiting
3
124
Europe, Canada, Japan, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Myasthenia Gravis, Ocular
12/25
12/27
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
10/24
10/24
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
RELIEVE, NCT06744920: A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
180
US, RoW
Remibrutinib (Blinded), LOU64, Placebo, Remibrutinib (Open Label), LOU064
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
02/28
02/33
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Active, not recruiting
2
30
Canada, US
Descartes-08
Cartesian Therapeutics
Myasthenia Gravis, Generalized
07/25
03/26
SYNAPSE-MG, NCT06414954: Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Recruiting
2
84
Europe, US, RoW
NMD670, Placebo
NMD Pharma A/S
Myasthenia Gravis, Myasthenia Gravis, MuSK
11/25
11/25
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
NCT06298565: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Recruiting
N/A
680
Europe, US
efgartigimod
argenx
Myasthenia Gravis
06/34
06/34
Schirtzer, Emily
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2/3
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
03/25
09/25
Andreen, Alyssa
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences, National Institute on Aging (NIA)
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
09/25
10/25
Coerver, Katherine
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Galloway, Christopher
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Completed
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
05/24
STEM-PD, NCT04797611: STEM-Parkinson's Disease

Completed
N/A
188
Europe, US
TNM Device, tvCVS
Scion NeuroStim
Parkinson Disease, Parkinson's Disease and Parkinsonism
12/24
12/24
Rice, Taylor
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
Feinberg, Marc
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
01/24
02/24
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
ADAPT oculus, NCT06558279: A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

Recruiting
3
124
Europe, Canada, Japan, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Myasthenia Gravis, Ocular
12/25
12/27
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
10/24
10/24
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
RELIEVE, NCT06744920: A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
180
US, RoW
Remibrutinib (Blinded), LOU64, Placebo, Remibrutinib (Open Label), LOU064
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
02/28
02/33
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Active, not recruiting
2
30
Canada, US
Descartes-08
Cartesian Therapeutics
Myasthenia Gravis, Generalized
07/25
03/26
SYNAPSE-MG, NCT06414954: Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Recruiting
2
84
Europe, US, RoW
NMD670, Placebo
NMD Pharma A/S
Myasthenia Gravis, Myasthenia Gravis, MuSK
11/25
11/25
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
NCT06298565: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Recruiting
N/A
680
Europe, US
efgartigimod
argenx
Myasthenia Gravis
06/34
06/34
Schirtzer, Emily
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2/3
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
03/25
09/25
Andreen, Alyssa
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences, National Institute on Aging (NIA)
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
09/25
10/25
Coerver, Katherine
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28

Download Options